Mediar Therapeutics
Mediar Therapeutics is a clinical-stage biotechnology company developing first-in-class therapies designed to halt fibrosis by targeting the myofibroblast, the key pathogenic cell driving scarring and organ failure. The company advances antibody therapeutics across multiple organ systems with programs in systemic sclerosis, idiopathic pulmonary fibrosis, and chronic kidney disease.
Leadership & Board
- Current Number of Employees
- 60
- Current LinkedIn Followers
- 5,782
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $76M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $76M
- Latest Funding Round
- Series B
- Post-Money Valuation
- ―
Company Momentum Positive
Mediar Therapeutics LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.
Employee Trend
Mediar Therapeutics had 60 employees as of October 12, 2026. The number of employees increased by 1 (1.69%) week-over-week.
Social Trend
Mediar Therapeutics had 5,782 followers as of October 12, 2026. The number of followers increased by 52 (0.91%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jan 07, 2026 | Series B | $76.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Longwood Fund | Series B |
| Amplitude Ventures | Series B |
| ICG | Series B |
| Asahi Kasei Pharma Ventures | Series B |
| Alexandria Real Estate Trust | Series B |
Similar Companies
A snapshot of private companies similar to Mediar Therapeutics, helping you discover and navigate related company profiles.
Related News and Analysis
